Medical Marijuana Genetics have been awarded for their incredible high-CBD strains for the second time this year, picking up two awards at Spannabis 2017 in Madrid.
The burgeoning new seedbank were awarded 2nd and 3rd place trophies in the CBD category for their strains Candida (CD-1) and Nightingale (NN-1) respectively. Earlier in the year, the company were also awarded 1st place in the CBD category for their Orinoco (OR-1) strain at Spannabis 2017 in Barcelona.
John Green, founder of Medical Marijuana Genetics spoke to us regarding the latest accolades;
“We are very lucky and proud to have the best breeding team recognised at Spannabis Madrid 2017, and for our strains Candida CD-1 and Nightingale NN-1 to take two prizes in the CBD category. With 3 out of our 7 available strains now recognised cup winners, we hope that all customers and patients can take the same pleasure and medical benefits that we know these strains can provide.”
The Winning Strains
Candida (CD-1) – Candida has the highest CBD and lowest THC content of any strain currently available on the world seed market. Laboratory tests show CBD levels of between 20.6% and 10.6% with THC levels rising higher with CBD levels – but never passing 1%.
With these ratios of CBD to THC, the anti-psychotic capabilities of the higher levels of CBD outweigh the relatively small amounts of THC and effectively remove the “high”, ensuring a non-psychoactive cannabis plant.
Nightingale (NN-1) – Nightingale, named after the founder of modern nursing Florence Nightingale is a poly hybrid indica bred from the legendary Shiskaberry and CD-1.
During testing, its CBD levels have ranged from 20.3% to 10.3%. The THC levels varied the most out of all strains sold by Medical Marijuana Genetics, meaning the strain varies from a 1:1 to a 20:1.
Candida (CD-1), Nightingale (NN-1) and all other strains in the Medical Marijuana Genetics collection are available to buy from Seedsman now.